DESs (drug-eluting) in Spain: 60% by end 2005:
This article was originally published in Clinica
By the end of 2005, around 60% of all coronary artery stents implanted in Spain will be drug-eluting (DESs) - up from a current estimated 35-40%. This is according to a study by Dr Eulogio Garcia, head of the department of haemodynamics at Madrid's Gregorio Maranon hospital. The study also found that around 35% of all Spanish implantees of bare metal stents (not drug-eluting) require surgery due to restenosis within six months of the initial operation, reports El Pais.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.